Rolf Einar Engstad

Director/Board Member at Biotec BetaGlucans AS

65 year

Health Technology

Consumer Services

Profile

Rolf Einar Engstad is currently the Director at Biotec BetaGlucans AS.
Previously, he worked as the Chief Scientific Officer at ArcticZymes Technologies ASA. He received his graduate and doctorate degrees from the University of Tromso.

Rolf Einar Engstad active positions

Companies	Position	Start
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Board Member	-

All active positions of Rolf Einar Engstad

Former positions of Rolf Einar Engstad

Companies	Position	End
ARCTICZYMES TECHNOLOGIES ASA	Chief Tech/Sci/R&D Officer	-

See the detail of Rolf Einar Engstad's experience

Training of Rolf Einar Engstad

University of Tromso

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Rolf Einar Engstad's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Private companies	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology